United Therapeutics Co. (NASDAQ:UTHR) CEO Sells $1,174,860.00 in Stock

United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $326.35, for a total transaction of $1,174,860.00. Following the sale, the chief executive officer now directly owns 130 shares of the company’s stock, valued at approximately $42,425.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

United Therapeutics Stock Down 1.6 %

UTHR stock traded down $5.37 during midday trading on Thursday, hitting $323.88. The company’s stock had a trading volume of 596,512 shares, compared to its average volume of 497,189. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.77 and a quick ratio of 3.64. United Therapeutics Co. has a twelve month low of $208.62 and a twelve month high of $330.00. The company’s fifty day moving average price is $287.54 and its 200 day moving average price is $248.48. The stock has a market capitalization of $14.37 billion, a P/E ratio of 15.57, a PEG ratio of 1.39 and a beta of 0.55.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.63 by $0.54. United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. The firm had revenue of $677.70 million for the quarter, compared to analyst estimates of $620.31 million. During the same period in the previous year, the business earned $4.86 EPS. The company’s revenue was up 33.7% compared to the same quarter last year. As a group, equities research analysts predict that United Therapeutics Co. will post 24.73 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of UTHR. Blue Trust Inc. increased its position in United Therapeutics by 10.0% in the 4th quarter. Blue Trust Inc. now owns 504 shares of the biotechnology company’s stock valued at $114,000 after acquiring an additional 46 shares during the period. MBM Wealth Consultants LLC increased its position in United Therapeutics by 2.7% in the 1st quarter. MBM Wealth Consultants LLC now owns 2,241 shares of the biotechnology company’s stock valued at $515,000 after acquiring an additional 59 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd increased its position in United Therapeutics by 1.6% in the 4th quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 3,892 shares of the biotechnology company’s stock valued at $856,000 after acquiring an additional 61 shares during the period. Janiczek Wealth Management LLC increased its position in United Therapeutics by 21.1% in the 1st quarter. Janiczek Wealth Management LLC now owns 482 shares of the biotechnology company’s stock valued at $111,000 after acquiring an additional 84 shares during the period. Finally, Compass Ion Advisors LLC increased its position in United Therapeutics by 3.6% in the 1st quarter. Compass Ion Advisors LLC now owns 2,892 shares of the biotechnology company’s stock valued at $664,000 after acquiring an additional 101 shares during the period. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on UTHR shares. Morgan Stanley cut shares of United Therapeutics from an “overweight” rating to an “equal weight” rating and lifted their price target for the stock from $310.00 to $321.00 in a research report on Thursday. HC Wainwright reissued a “buy” rating and set a $300.00 price target on shares of United Therapeutics in a research report on Thursday, May 2nd. TD Cowen boosted their price objective on shares of United Therapeutics from $270.00 to $350.00 and gave the company a “buy” rating in a research report on Thursday. StockNews.com cut shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, June 20th. Finally, The Goldman Sachs Group boosted their price objective on shares of United Therapeutics from $218.00 to $240.00 and gave the company a “neutral” rating in a research report on Friday, May 3rd. Two investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $321.55.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.